Clinical Trial

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis

Study acronym: AL-003
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-25; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-11-21
Trial Details
NCT Number NCT07151690
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Systemic Light Chain Amyloidosis
Enrollment 21 participants
Start Date 2025-09-04
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-23